Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd. | Director | Ordinary Shares | 1.49M | $26.7M | $18.01 | Oct 21, 2022 | Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd |
Eloxx Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 20K | Jun 15, 2022 | Direct | ||
Keros Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 10K | May 30, 2024 | Direct | ||
UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | Oct 21, 2022 | By Pontifax Cayman III Limited Partnership | ||
UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | Oct 21, 2022 | By Pontifax (Israel) III Limited Partnership |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KROS | Keros Therapeutics, Inc. | May 30, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director, 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Nov 29, 2022 | 6 | -$1 | 4 | Nov 30, 2022 | Director, 10%+ Owner |
URGN | UroGen Pharma Ltd. | Oct 21, 2022 | 3 | $285K | 4/A | Feb 28, 2023 | Director |
URGN | UroGen Pharma Ltd. | Jun 16, 2022 | 2 | $11.1K | 4 | Feb 28, 2023 | Director |
ELOX | Eloxx Pharmaceuticals, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
URGN | UroGen Pharma Ltd. | Jun 8, 2022 | 2 | $0 | 4 | Jun 10, 2022 | Director |
URGN | UroGen Pharma Ltd. | Jun 6, 2022 | 2 | $5.15K | 4/A | Feb 28, 2023 | Director |
KROS | Keros Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director, 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Jun 1, 2021 | 1 | $0 | 4 | Jun 3, 2021 | Director, 10%+ Owner |
ELOX | Eloxx Pharmaceuticals, Inc. | May 19, 2021 | 1 | $0 | 4 | May 20, 2021 | Director |
ELOX | Eloxx Pharmaceuticals, Inc. | May 13, 2021 | 4 | $8M | 4 | May 17, 2021 | Director |
URGN | UroGen Pharma Ltd. | Mar 25, 2021 | 2 | $5.15K | 4/A | Jun 9, 2021 | Director |
URGN | UroGen Pharma Ltd. | Mar 25, 2021 | 4 | $11.1K | 4 | Jun 9, 2021 | Director |
KROS | Keros Therapeutics, Inc. | Apr 7, 2020 | 0 | $0 | 3/A | Nov 30, 2022 | Director, 10%+ Owner |